MedTrace Logo

Post Approval Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft

NCT04261686 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-12-16

No results posted yet for this study

Summary

The objective of this study is to collect post-market, real-world safety and effectiveness data of the COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit.

Conditions

  • Arteriovenous Fistula

Interventions

DEVICE

Covera Vascular Covered Stent

This is a single-arm study. All subjects will receive the Covera Vascular Covered Stent

Sponsors & Collaborators

  • C. R. Bard

    lead INDUSTRY

Principal Investigators

  • Bart Dolmatch, M.D. · The Palo Alto Medical Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2025-09-16
Completion
2025-09-16
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04261686 on ClinicalTrials.gov